Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
Medical researchers are making unprecedented progress into understanding why women suffer disproportionately from a number of diseases. Those insights are providing information to help develop medicines to attack diseases such as osteoporosis, multiple sclerosis, depression, rheumatoid arthritis and age-related macular degeneration, all of which affect more women than men.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/phrma/50270/
University Hospitals (UH) Case Medical Center has announced a $250 million initiative that promises to dramatically change how drugs will advance from discovery in the laboratories to commercialization, resulting in greater access to advanced treatments and cures for patients. The first-of-its-kind initiative, named The Harrington Project for Discovery & Development, is powered by a $50 million gift – the largest donation in the health system’s history – from the Harrington family, recognized entrepreneurs and philanthropists in Cleveland.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54909-university-hospitals-uh-harrington-discovery-institute-development-project
Caralluma
Fimbriata is widely acknowledged as the MOST POWERFUL weight loss and
appetite suppressant that is completely natural and 100% side effect
free! To learn all about Caralluma and what it means for YOU CLICK http://carallumaforyou.com/ To learn about the bestselling Caralluma product CLICK http://carallumaforyou.com/caralluma-actives
CVS/pharmacy has kicked-off its ninth annual in-store fund raising campaign to support the fight against amyotrophic lateral sclerosis (ALS). Since 2002, CVS/pharmacy has partnered with the ALS Therapy Alliance (ATA) to help advance ALS research. To date, CVS/pharmacy has raised more than $19 million in its stores—a single $1 donation at a time—to support the funding of new clinical research with the aim of discovering a treatment or cure for this devastating disease. This year's campaign began on June 6 and runs through June 26.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cvs/44466/
Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market and manufacturer of the industry's three premier brands: Thermage®, Fraxel®, and Isolaz®, is pleased to announce that it has partnered with PGA TOUR golfer Scott McCarron to raise awareness about skin protection and the Fraxel re:store® laser treatment. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin, including the removal of actinic keratoses (AK’s ) — a precancerous skin condition caused by sun exposure. Fraxel re:store treatment provides superior results for AKs on the face or other areas of the body displaying the signs of photodamage.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/solta/45388/
Rules-Based Medicine, Inc. (RBM), today announced the widespread commercial availability of VeriPsych™, the first and only blood-based diagnostic test to aid in confirming the diagnosis of recent onset schizophrenia, a potentially devastating and costly mental illness that affects about 24 million people worldwide. VeriPsych is an innovative molecular diagnostic tool designed to complement the healthcare provider’s clinical impression.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/rulesbasedmedicine/46237/
As soon as you start feeling run down or have other flu-like symptoms, take Oscillococcinum.
Oscillo® is supported by published clinical studies, as well as more than 65 years of use throughout the world.
-Clinical studies show that Oscillo reduces the severity and duration of flu-like symptoms such as headache, body aches, chills and fever
-Great taste and convenient to take
-No side effects; no drug interactions; non-drowsy
-Safe for everyone 2 years of age and older
To view Multimedia News Release, go to http://www.multivu.com/players/English/45775-Boiron-Oscillococcinum/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
On June 5, CVS/pharmacy kicked-off its 10th annual in-store fundraising campaign -- “Researching a Cure” -- to support the fight against amyotrophic lateral sclerosis (ALS). Funds raised through the campaign benefit the ALS Therapy Alliance (ATA), a leading organization dedicated to advancing ALS research. Through the Researching a Cure campaign, CVS/pharmacy has raised more than $23 million in its stores and online at www.cvs.com, to fund new clinical research with the aim of discovering a treatment or cure for ALS. The 2011 campaign will run through June 25.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cvs/50475/
Today, a new study from P&G Beauty & Grooming and lead investigator Nancy Etcoff, PhD., Assistant Clinical Professor at Harvard University and Associate Researcher at Massachusetts General Hospital Department of Psychiatry, confirms for the first time that using color cosmetics does, in fact, significantly alter how women are perceived by others, at first glance and over time. Results of the study, published on October 3, 2011 in PLoS ONE, show that makeup application specifically impacts judgments of attractiveness and character when viewed rapidly or for unlimited amounts of time.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52087-p-g-harvard-study-reveals-cosmetics-alter-instinctual-perception
